PRESS RELEASE

Q1 2026 — Press release

Q1 2026PDF · 17 pages2.0 MB
For immediate release
Johnson & Johnson reports Q1 2026 results , raises 2026 outloo k
• 202 6 First -Quarter reported sales growth of 9.9% to $ 24 .1Billion with operational growth of 6.4%* and adjusted operational
growth of 5.3%*
• 202 6 Firs t-Quarter earnings per share (EPS) of $ 2.14 and adjusted EPS of $ 2.70
• Company increases 2026 guidance with estimated reported sales of $100.8 Billion or 7.0% at the midpoint, and adjusted
EPS 4 of $11.55 or 7.1% at the midpoint
• S olidify ing path to double -digit growth by the end of the decade , with significant progress for patients with the approvals of
ICOTYDE the first -and-only targeted oral peptide for plaque psoriasis, TECVAYLI plus DARZALEX FASPRO as early as second
line for patients with relapsed/refractory multiple myeloma, VARIPULSE P ro in Europe with a new pulse sequence that is now
5 times faster , and TECNIS PureSee Intraocular Lens for U.S. Cataract Patients
• Company announces planned Enterprise Business Review for December 8, 2026
New Brunswick, N.J. ( April 14 , 202 6) – Johnson & Johnson (NYSE: JNJ) today announced results for first -quarter 202 6.
“Johnson & Johnson had a strong start to 2026 and is delivering on its promise for a year of accelerated growth and impact,”
said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “The depth and strength of our portfolio and
pipeline is unrivaled and our relentless focus on innovation delivered multiple game -changing approvals this quarter, including
ICOTYDE in the U.S. for moderate to severe plaque psoriasis and VARIPULSE Pro in Europe. These advancements have the
potential to transform patient outcomes and create sustainable, long -term value for shareholders.”
Overall financial results
Q1
($ in Millions, except EPS) 2026 202 5 % Change
Reported Sales $24,062 $21,893 9.9%
Net Earnings $5,235 $10,999 -52.4%
EPS (diluted) $2.14 $4.54 -52.9%
Q1
Non -GAAP* ($ in Millions, except EPS) 2026 202 5 % Change
Operational Sales 1,2 6.4%
Adjusted Operational Sales 1,3 5.3%
Adjusted Net Earnings 1,4 $6,614 $6,706 -1.4%
Adjusted EPS (diluted) 1,4 $2.70 $2.77 -2.5%
Free Cash Flow 5,6 ~$1,500 $3,379
1 Non-GAAP financial measure; refer to reconciliations of non -GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
4 Excludes intangible amortization expense and special items
5 Non-GAAP measure; defined as cash flow from operating activities , less additions to property, plant and equipment . Cash flow from
operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings.
6 First -quarter 202 6 is estimated as of April 14, 202 6
Media contact:
media-relations@its.jnj.com
Investor contact:
investor -relations@its.jnj.com

-- 1 of 17 --

Note: values may have been rounded
Regional sales results
Q1 % Change
($ in Millions) 2026 202 5 Reported Operational 1,2 Currency
Adjusted
Operational 1,3
U.S. $ 13,330 $ 12,305 8.3 % 8.3 - 6.2
International 10,732 9,588 11.9 3.9 8.0 4.0
Worldwide $ 24,062 $ 21,893 9.9% 6.4 3.5 5.3
1 Non-GAAP financial measure; refer to reconciliations of non -GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded
Segment sales results
Q1 % Change
($ in Millions) 2026 202 5 Reported Operational 1,2 Currency
Adjusted
Operational 1,3
Innovative Medicine $ 15,426 $ 13,873 11.2% 7.4 3.8 5.6
MedTech 8,636 8,020 7.7 4.6 3.1 4.7
Worldwide $ 24,062 $ 21,893 9.9% 6.4 3.5 5.3
1 Non-GAAP financial measure; refer to reconciliations of non -GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded
First -Quarter 202 6 segment commentary:
Operational sales* reflected below excludes the impact of translational currency .
Innovative Medicine
Innovative Medicine worldwide operational sales grew 7.4%*, with net acquisitions and divestitures positively impacting growth
by 1.8% primarily due to CAPLYTA . Growth was driven primarily by DARZALEX, CARVYKTI, ERLEADA , and
RYBREVANT /L AZCLUZE in Oncology, TREMFYA in Immunology, and SPRAVATO in Neuroscience . Growth was partially offset by
an approximate (920 ) basis points impact from STELARA in Immunology , as well as IMBRUVICA in Oncology .
MedTech
MedTech worldwide operational sales grew 4.6 %*, with divestitures negatively impacting growth by 0.1%. Growth was driven
primarily by electrophysiology products , Abiomed , and Shockwave in Cardiovascular , as well as trauma in Orthop aedics .

-- 2 of 17 --

Full-year 202 6 guidance:
Johnson & Johnson does not provide GAAP financial measures on a forward -looking basis because the company is unable to
predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition -related
expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on
various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.
($ in Billions, except EPS) April 2026 January 2026
Adjusted Operational Sales 1,2
Change vs. Prior Year / Mid -point 5.6% – 6.6% / 6.1% 5.4% – 6.4% / 5.9%
Operational Sales 2 / Mid-point
Change vs. Prior Year / Mid -point
$99.7B – $100.7B / $100.2B
5.9% – 6.9% / 6.4%
$99.5B – $100.5B / $100.0B
5.7% – 6.7% / 6.2%
Estimated Reported Sales 3/ Mid-point
Change vs. Prior Year / Mid -point
$100.3B – $101.3B / $100.8B
6.5% – 7.5% / 7.0%
$100.0B – $101.0B / $100.5B
6.2% – 7.2% / 6.7%
Adjusted Operational EPS (Diluted) 2,4 / Mid-point
Change vs. Prior Year / Mid -point
$11.30 – $11.50 / $11.40
4.7% – 6.7% / 5.7%
$11.28 – $11.48 / $11.38
4.5% – 6.5% / 5.5%
Adjusted EPS (Diluted) 3,4 / Mid-point
Change vs. Prior Year / Mid -point
$11.45 – $11.65 / $11.55
6.1% – 8.1% / 7.1%
$11.43 – $11.63 / $11.53
5.9% – 7.9% / 6.9%
1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures
2 Non-GAAP financial measure; excludes the impact of translational currency
3 Calculated using Euro Average Rate: April 2026 = $ 1.17 and January 202 6 = $ 1.17 (Illustrative purposes only)
4 Non-GAAP financial measure; excludes intangible amortization expense and special items
Note: percentages may have been rounded
Other modeling considerations will be provided on the webcast .
Notable announcements in the quarter:
The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the
Securities and Exchange Commission, including its Current Reports on Form 8 -K, Quarterly Reports on Form 10 -Q and Annual
Reports on Form 10 -K. Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson &
Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations
section of the company’s website at Investor News , as well as Innovative Medicine Newsroom , MedTech News & Events , and
www.factsabouttalc.com .
Regulatory Johnson & Johnson Announces FDA Approval of TECNIS PureSee
Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients Press Release
Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI plus
DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma,
Offering a Potential New Standard of Care as Early as Second Line
Press Release
Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track
designation in systemic lupus erythematosus (SLE) Press Release
Johnson & Johnson seeks FDA approval of IMAAVY (nipocalimab -aahu)
as the first -ever FDA -approved treatment for warm autoimmune
hemolytic anemia (wAIHA)
Press Release
RYBREVANT FASPRO (amivantamab and hyaluronidase -lpuj) receives
U.S. FDA Breakthrough Therapy Designation for patients with advanced
head and neck cancer
Press Release
FDA approves RYBREVANT FASPRO (amivantamab and hyaluronidase -
lpuj) as the only EGFR -targeted therapy that can be administered once a
month
Press Release

-- 3 of 17 --

DARZALEX FASPRO -based quadruplet regimen approved in the U.S. for
newly diagnosed patients with multiple myeloma who are transplant
ineligible
Press Release
Data Releases Johnson & Johnson Highlights Favorable 12 -Month Interim Results for
the VARIPULSE Platform at EHRA 2026 1 Press Release
Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee
IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and
Extended Range of Vision 1
Press Release
STEMI DTU Randomized Control Trial Demonstrates for the First Time
that a Combination of Delayed Reperfusion and Left Ventricular
Unloading Does Not Increase Myocardial Infarct Size
Press Release
ICOTYDE (icotrokinra) one -year results confirm lasting skin clearance
and favorable safety profile in once ‑daily pill for plaque psoriasis Press Release
Johnson & Johnson highlights promising first -in-human Erda -iDRS
(formerly TAR -210) results in intermediate -risk non -muscle -invasive
bladder cancer
Press Release
Early study results from Johnson & Johnson show promising antitumor
activity with combination of pasritamig and docetaxel in advanced
prostate cancer
Press Release
TREMFYA (guselkumab) long -term data show sustained clinical and
endoscopic remission in ulcerative colitis through 3 years Press Release
RYBREVANT FASPRO (amivantamab and hyaluronidase -lpuj) plus
immunotherapy shows strong clinical benefit with 56 percent overall
response rate in first -line recurrent or metastatic head and neck cancer
Press Release
Johnson & Johnson Presents Early Outcomes from the OMNY -AF Pilot
Study at 2026 AF Symposium Press Release
Real -world head -to-head analysis shows 51% reduction in risk of death
for patients with metastatic castration -sensitive prostate cancer
treated with ERLEADA (apalutamide) versus darolutamide without
docetaxel through 24 months
Press Release
Product Launch
Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the
Launch of VARIPULSE Pro in Europe 1 Press Release
FDA approval of ICOTYDE (icotrokinra) ushers in new era for first -line
systemic treatment of plaque psoriasis with a targeted oral peptide Press Release
Other
Johnson & Johnson Expands U.S. Footprint with more than $1 Billion
Investment in Next Generation Cell Therapy Manufacturing Facility in
Pennsylvania
Press Release
1 Subsequent to the quarter
Webcast information:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8: 30 a.m., Eastern
Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson &
Johnson website . A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations
section of the company's website at events -and-presentations .
About Johnson & Johnson:
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world
where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are
personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full
spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
Learn more at www.jnj.com.

-- 4 of 17 --

Non-GAAP financial measures:
* “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth” excluding th e
net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”, “adjusted diluted
ear nings per share” and “adjusted operational diluted earnings per share” excluding after -tax intangible amortization expense
and special items, are non -GAAP financial measures and should not be considered replacements for, and should be read
together with, t he most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non -
GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial
schedules of the earnings release and the Investor Relations section of the company's website at quarterly results .
Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly
results . These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of
non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including
adjusted income before tax by segment, an Innovative Medicine pipeline of selected compounds in late stage development and
a copy of today’s earnings call presentation can also be found in the Investor Relations section of the company's website at
quarterly results .
Note to investors concerning forward -looking statements:
This press release contains “forward -looking statements” as defined in the Private Securities Litigation Reform Act of 1995
regarding, among other things: future operating and financial performance, product development, and market position and
business str ategy. The reader is cautioned not to rely on these forward -looking statements. These statements are based on
current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties
materialize, actual r esults could vary materially from the expectations and projections of Johnson & Johnson. Risks and
uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuation s or
changes to applicable laws and regulations; competition, including technological advances, new products and patents attained
by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and
obtaining regulatory approvals; unc ertainty of commercial success for new and existing products; challenges to patents; the
impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring pla ns;
the impact of business combinations an d divestitures; manufacturing difficulties or delays, internally or within the supply chain;
product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or
government action, including related to pr oduct liability claims; changes to applicable laws and regulations, including tax laws
and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of
purchasers of health care products and services; financial instability of international economies and legal systems and
sovereign risk; increased scrutiny of the health care industry by government agencies ; and the Company's ability to
successfully separate the Company's Orthopaedics business and realiz e the anticipated benefits from the planned separation .
A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most rece nt
Annual Report on Form 10 -K, including in the sections captioned “Cautionary Note Regarding Forward -Looking Statements” and
“Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10 -Q and other filings with the
Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov , www.jnj.com, investor.jnj.com ,
or on request from Johnson & Johnson. Any forward -looking statement made in this release speaks only as of the date of this
release. Johnson & Johnson does not undertake to update any forward -looking statement as a result of new information or
future eve nts or developments .

-- 5 of 17 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
2026 2025 Total Operations Currency
Sales to customers by
segment of business
Innovative Medicine
U.S. 8,871	$ 8,092 9.6 % 9.6 -
International 6,555 5,781 13.4 4.3 9.1
15,426 13,873 11.2 7.4 3.8
MedTech
U.S. 4,459 4,213 5.9 5.9 -
International 4,177 3,807 9.7 3.2 6.5
8,636 8,020 7.7 4.6 3.1
U.S. 13,330 12,305 8.3 8.3 -
International 10,732 9,588 11.9 3.9 8.0
Worldwide 24,062	$ 21,893 9.9 % 6.4 3.5
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
FIRST QUARTER
Percent Change

-- 6 of 17 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
2026 2025 Total Operations Currency
Sales to customers by
geographic area
U.S. 13,330	$ 12,305 8.3 % 8.3 -
Europe 5,848 5,110 14.5 2.7 11.8
Western Hemisphere excluding U.S. 1,293 1,167 10.8 2.5 8.3
Asia-Pacific, Africa 3,591 3,311 8.5 6.1 2.4
International 10,732 9,588 11.9 3.9 8.0
Worldwide 24,062	$ 21,893 9.9 % 6.4 3.5
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
FIRST QUARTER
Percent Change

-- 7 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
INNOVATIVE MEDICINE SEGMENT (2) 2026 2025 Reported Operational (1) Currency
ONCOLOGY
US 3,615	$ 3,013 20.0% 20.0% -
Intl 3,358 2,664 26.0% 15.3% 10.7%
WW 6,973 5,678 22.8% 17.8% 5.0%
DARZALEX
US 2,208 1,829 20.7% 20.7% -
Intl 1,756 1,409 24.7% 14.0% 10.7%
WW 3,964 3,237 22.5% 17.8% 4.7%
CARVYKTI
US 433 318 36.2% 36.2% -
Intl 164 51 * * *
WW 597 369 62.1% 57.4% 4.7%
TECVAYLI
US 127 105 20.6% 20.6% -
Intl 74 46 63.1% 52.1% 11.0%
WW 202 151 33.5% 30.1% 3.4%
TALVEY
US 101 68 48.5% 48.5% -
Intl 51 18 * * *
WW 152 86 76.7% 72.8% 3.9%
RYBREVANT / LAZCLUZE
US 175 113 55.1% 55.1% -
Intl 82 28 * * *
WW 257 141 82.7% 80.5% 2.2%
ERLEADA
US 342 292 17.3% 17.3% -
Intl 607 479 26.7% 15.5% 11.2%
WW 949 771 23.1% 16.2% 6.9%
IMBRUVICA
US 143 235 (39.1)% (39.1)% -
Intl 517 474 9.1% (1.4)% 10.5%
WW 660 709 (6.9)% (13.9)% 7.0%
OTHER ONCOLOGY (3)
US 85 54 58.8% 58.8% -
Intl 106 160 (33.9)% (36.3)% 2.4%
WW 192 214 (10.6)% (12.5)% 1.9%
See footnotes at end of schedule
% Change

-- 8 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
2026 2025 Reported Operational (1) Currency
IMMUNOLOGY
US 1,855	$ 2,196 (15.5)% (15.5)% -
Intl 1,524 1,510 0.9% (6.4)% 7.3%
WW 3,380 3,707 (8.8)% (11.8)% 3.0%
TREMFYA
US 1,042 599 73.9% 73.9% -
Intl 566 356 58.9% 46.8% 12.1%
WW 1,608 956 68.3% 63.8% 4.5%
SIMPONI / SIMPONI ARIA
US 269 292 (7.8)% (7.8)% -
Intl 378 366 3.0% (4.1)% 7.1%
WW 647 659 (1.7)% (5.7)% 4.0%
REMICADE
US 269 314 (14.4)% (14.4)% -
US Exports (4) 18 10 78.6% 78.6% -
Intl 136 143 (4.8)% (10.5)% 5.7%
WW 422 467 (9.5)% (11.2)% 1.7%
STELARA
US 220 981 (77.6)% (77.6)% -
Intl 435 644 (32.4)% (37.7)% 5.3%
WW 656 1,625 (59.7)% (61.7)% 2.0%
OTHER IMMUNOLOGY
US 38 1 * * -
Intl 9 0 * * *
WW 46 1 * * *
NEUROSCIENCE
US 1,494 968 54.3% 54.3% -
Intl 681 679 0.3% (6.3)% 6.6%
WW 2,175 1,647 32.0% 29.3% 2.7%
SPRAVATO
US 406 276 47.0% 47.0% -
Intl 61 43 42.4% 28.7% 13.7%
WW 468 320 46.4% 44.5% 1.9%
CAPLYTA (5)
US 270 - * * -
Intl - - - - -
WW 270 - * * -
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 758 625 21.2% 21.2% -
Intl 280 277 1.1% (4.9)% 6.0%
WW 1,038 903 15.0% 13.2% 1.8%
CONCERTA / Methylphenidate
US 22 38 (43.4)% (43.4)% -
Intl 115 110 4.3% (0.6)% 4.9%
WW 136 148 (8.0)% (11.7)% 3.7%
OTHER NEUROSCIENCE
US 38 28 32.6% 32.6% -
Intl 224 248 (9.7)% (16.3)% 6.6%
WW 262 277 (5.4)% (11.3)% 5.9%
See footnotes at end of schedule
% Change

-- 9 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
2026 2025 Reported Operational (1) Currency
PULMONARY HYPERTENSION (PH)
US 831	$ 744 11.7% 11.7% -
Intl 304 281 8.2% 1.0% 7.2%
WW 1,135 1,025 10.7% 8.7% 2.0%
UPTRAVI
US 385 365 5.4% 5.4% -
Intl 98 86 14.3% 5.1% 9.2%
WW 483 451 7.1% 5.4% 1.7%
OPSUMIT / OPSYNVI
US 433 363 19.3% 19.3% -
Intl 172 159 8.7% 1.7% 7.0%
WW 606 522 16.1% 14.0% 2.1%
OTHER PULMONARY HYPERTENSION
US 12 15 (21.1)% (21.1)% -
Intl 34 37 (8.3)% (11.8)% 3.5%
WW 46 52 (12.1)% (14.5)% 2.4%
INFECTIOUS DISEASES (ID)
US 342 315 8.6% 8.6% -
Intl 547 487 12.2% 1.3% 10.9%
WW 889 802 10.8% 4.1% 6.7%
EDURANT / rilpivirine
US 7 8 (13.1)% (13.1)% -
Intl 402 350 14.8% 3.2% 11.6%
WW 409 358 14.1% 2.8% 11.3%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 334 305 9.5% 9.5% -
Intl 109 98 11.2% 0.7% 10.5%
WW 443 403 10.0% 7.4% 2.6%
OTHER INFECTIOUS DISEASES
US 1 2 (56.9)% (56.9)% -
Intl 36 39 (8.3)% (14.7)% 6.4%
WW 37 41 (10.4)% (16.5)% 6.1%
CARDIOVASCULAR / METABOLISM / OTHER (CVM)
US 734 855 (14.2)% (14.2)% -
Intl 142 158 (10.4)% (17.5)% 7.1%
WW 876 1,013 (13.6)% (14.7)% 1.1%
XARELTO
US 642 690 (7.0)% (7.0)% -
Intl - - - - -
WW 642 690 (7.0)% (7.0)% -
OTHER
US 91 165 (44.5)% (44.5)% -
Intl 142 158 (10.4)% (17.5)% 7.1%
WW 233 323 (27.8)% (31.2)% 3.4%
TOTAL PH, ID, CVM
US 1,907 1,914 (0.4)% (0.4)% -
Intl 993 926 7.1% (2.0)% 9.1%
WW 2,899 2,840 2.1% (0.9)% 3.0%
TOTAL INNOVATIVE MEDICINE
US 8,871 8,092 9.6% 9.6% -
Intl 6,555 5,781 13.4% 4.3% 9.1%
WW 15,426	$ 13,873 11.2% 7.4% 3.8%
See footnotes at end of schedule
% Change

-- 10 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
MEDTECH SEGMENT (2) 2026 2025 Reported Operational (1) Currency
CARDIOVASCULAR
US 1,399 1,261 10.9% 10.9% -
Intl 978 842 16.1% 9.9% 6.2%
WW 2,377 2,103 13.0% 10.5% 2.5%
ELECTROPHYSIOLOGY
US 736 684 7.6% 7.6% -
Intl 753 638 18.0% 11.7% 6.3%
WW 1,489 1,323 12.6% 9.5% 3.1%
ABIOMED
US 389 339 14.5% 14.5% -
Intl 100 81 23.5% 13.9% 9.6%
WW 488 420 16.3% 14.4% 1.9%
SHOCKWAVE
US 242 206 17.8% 17.8% -
Intl 63 52 21.3% 19.3% 2.0%
WW 305 258 18.5% 18.1% 0.4%
OTHER CARDIOVASCULAR
US 32 32 0.7% 0.7% -
Intl 62 72 (13.4)% (17.5)% 4.1%
WW 94 103 (9.1)% (11.9)% 2.8%
SURGERY
US 1,046 1,002 4.4% 4.4% -
Intl 1,465 1,394 5.1% (1.1)% 6.2%
WW 2,511 2,396 4.8% 1.2% 3.6%
ADVANCED
US 477 457 4.2% 4.2% -
Intl 646 616 4.9% (1.0)% 5.9%
WW 1,123 1,073 4.6% 1.2% 3.4%
GENERAL
US 569 544 4.5% 4.5% -
Intl 819 778 5.2% (1.3)% 6.5%
WW 1,388 1,323 4.9% 1.1% 3.8%
See footnotes at end of schedule
% Change

-- 11 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
2026 2025 Reported Operational (1) Currency
VISION
US 579 566 2.4% 2.4% -
Intl 785 713 10.1% 4.6% 5.5%
WW 1,365 1,279 6.7% 3.6% 3.1%
CONTACT LENSES / OTHER
US 468 452 3.7% 3.7% -
Intl 501 467 7.2% 1.7% 5.5%
WW 969 919 5.5% 2.7% 2.8%
SURGICAL
US 111 114 (2.9)% (2.9)% -
Intl 285 246 15.6% 10.1% 5.5%
WW 396 361 9.7% 6.0% 3.7%
ORTHOPAEDICS
US 1,435 1,384 3.7% 3.7% -
Intl 948 857 10.6% 2.4% 8.2%
WW 2,383 2,241 6.3% 3.2% 3.1%
HIPS
US 277 263 5.2% 5.2% -
Intl 159 146 8.9% 0.3% 8.6%
WW 436 409 6.5% 3.5% 3.0%
KNEES
US 239 231 3.3% 3.3% -
Intl 181 158 14.6% 6.5% 8.1%
WW 420 389 7.9% 4.6% 3.3%
TRAUMA
US 532 502 6.1% 6.1% -
Intl 301 270 11.4% 3.1% 8.3%
WW 833 772 8.0% 5.0% 3.0%
SPINE, SPORTS & OTHER
US 387 388 (0.1)% (0.1)% -
Intl 307 283 8.4% 0.7% 7.7%
WW 694 671 3.5% 0.2% 3.3%
TOTAL MEDTECH
US 4,459 4,213 5.9% 5.9% -
Intl 4,177 3,807 9.7% 3.2% 6.5%
WW 8,636	$ 8,020 7.7% 4.6% 3.1%
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Includes the sales of ZYTIGA which were previously disclosed separately
(4) Reported as U.S. sales
(5) Acquired with Intra-Cellular Therapies on April 2, 2025
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely
% Change

-- 12 of 17 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers 24,062	$ 100.0 21,893	$ 100.0 9.9
Cost of products sold 8,106 33.7 7,357 33.6 10.2
Gross Profit 15,956 66.3 14,536 66.4 9.8
Selling, marketing and administrative expenses 6,034 25.1 5,112 23.3 18.0
Research and development expense 3,527 14.7 3,225 14.7 9.4
In-process research and development impairments 36 0.1 - -
Interest (income) expense, net 43 0.2 (128) (0.6)
Other (income) expense, net 294 1.2 (7,321) (33.4)
Restructuring 32 0.1 17 0.1
Earnings before provision for taxes on income 5,990 24.9 13,631 62.3 (56.1)
Provision for taxes on income 755 3.1 2,632 12.1 (71.3)
Net earnings 5,235	$ 21.8 10,999	$ 50.2 (52.4)
Net earnings per share (Diluted) 2.14	$ 4.54	$ (52.9)
Average shares outstanding (Diluted) 2,445.2 2,423.8
Effective tax rate 12.6 % 19.3 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 7,821	$ 32.5 8,011	$ 36.6 (2.4)
Net earnings 6,614	$ 27.5 6,706	$ 30.6 (1.4)
Net earnings per share (Diluted) 2.70	$ 2.77	$ (2.5)
Effective tax rate 15.4 % 16.3 %
(1) See Reconciliation of Non-GAAP Financial Measures.
FIRST QUARTER
2026 2025

-- 13 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Innovative Medicine MedTech Total
WW As Reported 11.2% 7.7% 9.9%
U.S. 9.6% 5.9% 8.3%
International 13.4% 9.7% 11.9%
WW Currency 3.8 3.1 3.5
U.S. - - -
International 9.1 6.5 8.0
WW Operational 7.4% 4.6% 6.4%
U.S. 9.6% 5.9% 8.3%
International 4.3% 3.2% 3.9%
Caplyta (1.9) (1.2)
U.S. (3.3) (2.2)
International 0.0 0.0
All Other Acquisitions and Divestitures (A&D) 0.1 0.1 0.1
U.S. 0.0 0.2 0.1
International 0.2 0.0 0.1
WW Adjusted Operational Ex A&D 5.6% 4.7% 5.3%
U.S. 6.3% 6.1% 6.2%
International 4.5% 3.2% 4.0%
Adjusted Operational Sales Growth
FIRST QUARTER 2026 ACTUAL vs. 2025 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 14 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 2026 2025
Net Earnings, after tax- as reported $5,235 $10,999
Pre-tax Adjustments
Intangible Asset Amortization expense 1,247 1,120
Litigation related 330 (6,966)
Orthopaedics Separation related 119 -
Acquisition, integration and divestiture related 96 132
Restructuring related 1 62 55
IPR&D impairments 36 -
(Gains)/losses on securities (59) 39
Tax Adjustments
Tax impact on special item adjustments 2 (424) 1,315
Tax legislation and other tax related (28) 12
Adjusted Net Earnings, after tax $6,614 $6,706
Average shares outstanding (Diluted) 2,445.2 2,423.8
Adjusted net earnings per share (Diluted) $2.70 $2.77
Operational adjusted net earnings per share (Diluted) $2.57
Notes:
1
2
First Quarter
In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting
certain markets, product lines and distribution network arrangements. The restructuring expense of $7 million in the fiscal first quarter of 2026 and $55
million in the fiscal first quarter of 2025 primarily includes costs related to market and product exits. This program was substantially completed in Q4 2025.
In fiscal 2025, the company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting
certain non-strategic product lines and optimize select sites across the network. The restructuring expense of $55 million in the fiscal first quarter of 2026
primarily includes costs related to product exits. This program is expected to be substantially completed by the end of fiscal year 2026.
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving
at adjusted earnings.

-- 15 of 17 --

Year to Date
Innovative Medicine
First Quarter
Mar. 29, 2026
GAAP
Intangible asset
amortization Litigation related
In-process
research and
development
impairments
Restructuring
related
Acquisition, integration
and divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation Related
Tax legislation
and other tax
related
First Quarter
Mar. 29, 2026
Non-GAAP
Cost of products sold 4,390	$ (763) (10) 3,617	$
Selling, marketing and admin expenses 2,918 2,918
Research and development expense 2,813 2,813
Other segment items (12) (40) (46) 55 (43)
Adjusted Income Before Tax by Segment 5,317 763 40 - - 56 (55) - - 6,121
MedTech
First Quarter
Mar. 29, 2026
GAAP
Intangible asset
amortization Litigation related
In-process
research and
development
impairments
Restructuring
related
Acquisition, integration
and divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation Related
Tax legislation
and other tax
related
First Quarter
Mar. 29, 2026
Non-GAAP
Cost of products sold 3,701	$ (484) (25) 3,192	$
Selling, marketing and admin expenses 2,906 2,906
Research and development expense 714 714
Other segment items 76 41 (36) (37) (27) 4 (119) (98)
Adjusted Income Before Tax by Segment 1,239 484 (41) 36 62 27 (4) 119 - 1,922
Expenses not allocated to segments
First Quarter
Mar. 29, 2026
GAAP
Intangible asset
amortization Litigation related
In-process
research and
development
impairments
Restructuring
related
Acquisition, integration
and divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation Related
Tax legislation
and other tax
related
First Quarter
Mar. 29, 2026
Non-GAAP
Cost of products sold 15	$ 15	$
Selling, marketing and admin expenses 210 210
Research and development expense - -
Other segment items 341 (331) (13) (3)
Adjusted Income Before Tax by Segment (566) - 331 - - 13 - - - (222)
Johnson & Johnson Consolidated
First Quarter
Mar. 29, 2026
GAAP
Intangible asset
amortization Litigation related
In-process
research and
development
impairments
Restructuring
related
Acquisition, integration
and divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation Related
Tax legislation
and other tax
related
First Quarter
Mar. 29, 2026
Non-GAAP
Cost of products sold 8,106	$ (1,247) (25) (10) 6,824	$
Selling, marketing and admin expenses 6,034 6,034
Research and development expense 3,527 3,527
Other (Income) / Expense 294 (330) (5) (86) 59 (119) (187)
In-process research and development impairments 36 (36) -
Interest (Income)/Expense 43 43
Restructuring 32 (32) -
Adjusted Income Before Tax 5,990 1,247 330 36 62 96 (59) 119 - 7,821
Provision for taxes on income 755 240 72 8 70 22 (13) 25 28 1,207
Net Earnings 5,235	$ 1,007 258 28 (8) 74 (46) 94 (28) 6,614
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions

-- 16 of 17 --

Innovative Medicine
First Quarter
March 30, 2025
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Acquisition, integration
and divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related
First Quarter
March 30, 2025
Non-GAAP
Cost of products sold 4,020	$ (649) 3,371
Selling, marketing and admin expenses 2,261 2,261
Research and development expense 2,548 2,548
Other segment items (166) - - - (20) (18) - (204)
Adjusted Income Before Tax by Segment 5,210 649 - - 20 18 - 5,897
MedTech
First Quarter
March 30, 2025
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Acquisition, integration
and divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related
First Quarter
March 30, 2025
Non-GAAP
Cost of products sold 3,326	$ (471) (8) (52) 2,795
Selling, marketing and admin expenses 2,656 2,656
Research and development expense 677 (6) 671
Other segment items (60) - - (47) (54) (21) - (182)
Adjusted Income Before Tax by Segment 1,421 471 - 55 112 21 - 2,080
Expenses not allocated to segments
First Quarter
March 30, 2025
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Acquisition, integration
and divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related
First Quarter
March 30, 2025
Non-GAAP
Cost of products sold 11	$ 11
Selling, marketing and admin expenses 195 195
Research and development expense -
Other segment items (7,206) - 6,966 - - - - (240)
Adjusted Income Before Tax by Segment 7,000 - (6,966) - - - - 34
Johnson & Johnson Consolidated
First Quarter
March 30, 2025
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Acquisition, integration
and divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related
First Quarter
March 30, 2025
Non-GAAP
Cost of products sold 7,357	$ (1,120) (8) (52) - 6,177
Selling, marketing and admin expenses 5,112 5,112
Research and development expense 3,225 (6) 3,219
Other (Income) / Expense (7,321) - 6,966 (30) (74) (39) (498)
In-process research and development impairments - -
Interest (Income)/Expense (128) (128)
Restructuring 17 (17) -
Adjusted Income Before Tax 13,631 1,120 (6,966) 55 132 39 - 8,011
Provision for taxes on income 2,632 188 (1,553) 11 30 9 (12) 1,305
Net Earnings 10,999 932 (5,413) 44 102 30 12 6,706
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Year to Date

-- 17 of 17 --